Search Results

Zafirlukast 200 mg  | Purity Not Available

TargetMol

Zafirlukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma.

More Information Supplier Page

dBET1 25 mg  | Purity Not Available

TargetMol

dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.

More Information Supplier Page

dBET1 10 mg  | Purity Not Available

TargetMol

dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.

More Information Supplier Page

dBET1 5 mg  | Purity Not Available

TargetMol

dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.

More Information Supplier Page

SR-18292 100 mg  | 99.27%

TargetMol

SR-18292 is an inhibitor of PPAR gamma coactivator-1α (PGC-1α), which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.

More Information Supplier Page